| Literature DB >> 16859567 |
Judith L Ngondi1, Julius Oben, David Musoro Forkah, Lucten Honore Etame, Dora Mbanya.
Abstract
The study assessed the effect of some highly active antiretroviral therapies (HAART), used in the management of HIV/AIDS in Cameroon, on oxidative stress markers such as malondialdehyde (as TBARs), albumin, protein carbonyl content and protein sulfhydryls groups. 85 HIV positive patients (34.8 +/- 9.3 years) were on three different highly active antiretroviral therapies (HAART patients). 65 HIV positive patients (32.2 +/- 10.9 years) on no treatment (Pre-HAART patients), and 90 non-HIV infected patients (32.6 +/- 9.3 years), were the control groups. Plasma TBARs as well as carbonyl levels were significantly higher in HIV patients on HAART compared to pre-HAART patients or non-HIV infected controls. On the other hand, the protein sulfhydryl group content was not different for patients on HAART compared to pre-HAART patients, but both were significantly lower than non-HIV infected controls (P < 0.0001, 0.001). The combination treatment Therapy I [stavudin (80 mg) + Lamivudin (600 mg) + Nevirapin + (400 mg) zidovudin (600 mg)] brought about a significant (p < 0.05) reduction in the plasma concentration of protein sulfhydrl groups as well as TBARs compared to Therapy II [stavudin (80 mg) + Lamivudin (300 mg) + nevirapin (400 mg)] or with combination Therapy III of [zidovudine (600 mg) + lamivudin(300 mg) with efavirenz (600 mg)] (P < 0.05). The content of the antioxidant, Vitamin C was lower in the plasma of patients on Therapy I compared to those on Therapy II (P < 0.01) and Therapy III (P < 0.001). HIV infection therefore increases the oxidative stress process, while antiretroviral combination therapy increased protein oxidation as well as the level of oxidative stress already present in HIV infection.Entities:
Year: 2006 PMID: 16859567 PMCID: PMC1557529 DOI: 10.1186/1742-6405-3-19
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Characteristics of HIV positive patients on antiviral therapy, without therapy and controls
| 90 | 65 | 85 | |
| 20/70 | 27/38 | 30/55 | |
| 34 ± 9.15 | 33.71 ± 8.56 | 36.8 ± 8.91 | |
| 25.31 ± 2.44 | 25.01 ± 3.66 | 25.19 ± 4.70 | |
| / | 496 ± 163 | 266 ± 137a | |
| / | 26754 ± 8347 | 111136,33 ± 25281a |
Significant differences (aP < 0.0001) are by comparison with the HIV positive patients without therapy (pre-HAART)
The effect of HIV infection and the antiretroviral therapy, on markers of oxidative stress (carbonyls and TBARs).
| 1.07 ± 0.27 | 1.34 ± 0.98a | 0.84 ± 0.90a | |
| 1.3 ± 0.12 | 4.2 ± 0.77a | 6.28 ± 1.3ab | |
Significant differences (a P < 0.0001) are by comparison with the control group (HIV Negative), (b P < 0.0001) by comparison with the HIV positive patients without therapy (pre-HAART)
The effect of HIV infection and the antiretroviral therapy, on plasma levels of antioxidants.
| 8.03 ± 0.68 | 4.90 ± 2.78a | 3.87 ± 2.85a | |
| 0.94 ± 0.32 | 0.41 ± 0.05a | 0.49 ± 0.28ab | |
| 27.1 ± 4.22 | 26 ± 4.01 | 21.43 ± 4.53 | |
Significant differences (aP < 0.0001) are by comparison with the control group (HIV Negative), (bP < 0.0001) are by comparison with the HIV positive patients without therapy (pre-HAART)
The effect of HIV infection and different types of antiretroviral therapy, on markers of oxidative stress (carbonyls and TBARs).
| 1.07 ± 0.27 | 1.34 ± 0.98a | 0.79 ± 0.10ab | 0.93 ± 0.16b | 0.81 ± 0.09ab | |
| 1.30 ± 0.12 | 4.20 ± 0.70a | 7.02 ± 2.58ab | 5.92 ± 1.46ab | 5.84 ± 0.89ab | |
Significant differences (a P < 0.01) are by comparison with the control group (HIV Negative), (b P < 0.001) are by comparison with the HIV positive patients without therapy (pre-HAART)
The effect different types of antiretroviral therapy, on plasma levels of antioxidants.
| 8.03 ±± 0.68 | 4.90 ± 2.78a | 4.5 ± 2.1a | 2.70 ± 1.45abc | 4.37 ± 2.01a | |
| 0.94 ± 0.32 | 0.41 ± 0.05a | 0.47 ± 0.24a | 0.54 ± 0.31ab | 0.47 ± 0.29a | |
| 27.1 ± 4.22 | 26 ± 4.01 | 12.9 ± 2.12ab | 22.9 ± 5.01c | 28.5 ± 7.45c | |
Significant differences (aP < 0.001) are by comparison with the control group (HIV Negative), (bP < 0.01) are by comparison with the HIV positive patients without therapy (pre-HAART) and (cP < 0.001) by comparison with the HIV positive patients on therapy I
The effect of weight status on Oxidative stress markers levels of HIV infected patients
| 20–25 | ≥ 25 | <20 | 20–25 | ≥ 25 | |
| 22 (33.9%) | 43 (66.1%) | 10 (11.8%) | 42 (49.4%) | 33 (38.8%) | |
| 22.88 ± 0.48 | 27.63 ± 0.64 | 18.61 ± 0.32 | 23.04 ± 0.37 | 30.01 ± 0.94 | |
| 0.35 ± 0.03 | 0.51 ± 0.026c | 0.57 ± 0.03 | 0.47 ± 0.027 | 0.40 ± 0.045 | |
| 5.02 ± 1.48 | 4.80 ± 2.12 | 3.60 ± 2.1 | 5.12 ± 2.5 | 3.39 ± 0.95b | |
| 4.09 ± 0.57 | 4.50 ± 0.77 | 5.57 ± 1.29 | 6.76 ± 1.50 | 6.40 ± 1.43 | |
| 0.93 ± 0.14 | 0.90 ± 0.2 | 1.09 ± 0.24 | 0.82 ± 0.15a | 0.78 ± 0.11a | |
Significant differences (aP < 0.01) are by comparison with BMI Sub class <20 kg/m2
Significant differences (bP < 0.01;cP < 0.004) are by comparison with BMI Sub class 20–25 kg/m2
Comparison of oxidative stress markers levels between HIV infected patients with and without hypoalbuminemia
| <0.507 | ≥ 0.507 | <0.507 | ≥ 0.507 | |
| 35 (53.9%) | 30 (25.9%) | 63 (74.9%) | 22 (25.9%) | |
| 23.87 ± 0.65 | 27.83 ± 1.15** | 25.11 ± 0.96 | 25.54 ± 1.47 | |
| 0.35 ± 0.094 | 0.57 ± 0.05*** | 0.33 ± 0.017 | 0.55 ± 0.018*** | |
| 345.71 ± 59.58 | 582.25 ± 102.49** | 258 ± 42.04 | 269.38 ± 45.38 | |
| 4.73 ± 1.49 | 5.07 ± 2.7 | 3.52 ± 1.59 | 4.24 ± 2.71 | |
| 3.95 ± 0.56 | 4.72 ± 0.64** | 6.79 ± 1.21 | 6.11 ± 1.75* | |
| 0.95 ± 0.17 | 0.81 ± 0.16 | 0.82 ± 0.16 | 0.85 ± 0.18 | |
Significant differences (*P < 0.05; **P < 0.001; ***P < 0.0001) are by comparison with albumin Sub class <0.507 mol/l
Multiple linear regression analysis showing the influence of BMI, age, sex, CD4 count and Viral load on oxidative stress markers in HAART patients
| 0.093 | 0.140 | 0.026 | -0.139 | 0.176 | |
| 0.104 | -0.030 | 0.015 | 0.420** | -0.407** | |
| 0.170 | 0.060 | 0.185 | -0.190 | 0.102 | |
| -0.067 | -0.010 | 0.010 | -0.091 | -0.084 | |
| 0.345* | -0.011 | 0.030 | 0.320* | -0.366* | |
* p < 0.05, **p < 0.01.
Comparison of oxidative stress markers levels between HIV infected patients with and without the CD4<200 lymphocytes/mm3
| <200 | ≥ 200 | <200 | ≥ 200 | |
| 28 (43,18%) | 37 (56.82%) | 44 (51.7%) | 41(48.3%) | |
| 23.91 ± 0.64 | 26.92 ± 1.09* | 26.29 ± 1.39 | 25.22 ± 0.98 | |
| 0.39 ± 0.08 | 0.57 ± 0.13 | 0.50 ± 0.10 | 0.47 ± 0.15 | |
| 93.37 ± 13.01 | 434.21 ± 71.56** | 73.26 ± 15.18 | 341.83 ± 30.44** | |
| 4. 85 ± 1.30 | 4.94 ± 2.5 | 4.30 ± 2.7 | 3.59 ± 1.20 | |
| 4.31 ± 0.47 | 4.82 ± 0.7 | 6.80 ± 1.62 | 5.82 ± 1.17 | |
| 1.45 ± 0.10 | 1.17 ± 0.16 | 0.83 ± 0.20 | 0.86 ± 0.14 | |
Significant differences (**P < 0.005; **P < 0.0001) are by comparison with CD4 Sub class <200 lymphocytes/mm3